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A B S T R A C T   
Background: Poor sleep is a major complaint of people with human immunodeficiency virus (HIV) and acquired 
immune deficiency syndrome (AIDS) and undergoing methadone maintenance therapy (MMT). We tested the 
impact of three different sleep-improving interventions (trazodone; sleep hygiene training; sleep hygiene 
training + trazodone) on sleep, psychological functioning and biomarkers in males with HIV and undergoing 
MMT. 
Methods: A total of 75 male outpatients (mean age: 39.6 years) participated in a 12 week intervention. Partic-
ipants were randomly assigned to one of the following conditions: trazodone 50 mg/d (TRAZ); sleep hygiene 
training (SHT); sleep hygiene training and trazodone (SHT + TRAZ). At baseline, and six and 12 weeks later, 
participants completed questionnaires covering subjective sleep and daytime sleepiness, and symptoms of 
depression and anxiety. In parallel, their cognitive performance (working memory; sustained attention) was 
assessed. Biomarkers (cortisol, BNDF, CD4+) were assessed at baseline and at the end of the study. 
Results: Over time, sleep disturbances decreased and daytime functioning and overall sleep quality improved. 
More specifically, both sleep disturbances and daytime functioning improved in the two SHT conditions from 
baseline to week 6. Daytime functioning remained stable from week 6 to week 12. Over time, in all conditions 
symptoms of depression and anxiety declined from baseline to week 6 and remained lower from week 6 to week 
12. Daytime sleepiness, symptoms of insomnia and sleep-disordered breathing remained unchanged. Sustained 
attention performance improved over time from baseline to week 6 and remained high through to week 12. 
Biomarkers remained unchanged. 
Conclusions: In males with HIV and undergoing MMT, treating sleep disturbances over a period of six to 12 weeks 
had a positive impact on aspects of sleep disturbance, symptoms of depression and anxiety, and cognitive per-
formance. The results indicate that sleep hygiene training, either as stand-alone or in combination with trazo-
done, can produce positive results.   
1. Introduction 
Individuals with opioid use disorder (OUD) sharing needles and 
having unprotected sex with multiple partners are at increased risk of 
acquiring human immunodeficiency virus (HIV), and of suffering sub-
sequently from both acquired immunodeficiency syndrome (AIDS) and 
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hepatitis C virus (HCV). HIV, AIDS and HCV require life-long treatment. 
Methadone-maintenance therapy (MMT) now plays a key role in 
decreasing drug use and drug-related behavior such as sharing needles, 
working for commercial sex, having unprotected sex with multiple 
partners, and committing drug- and sex-related crimes (Gowing et al., 
2006; Wodak and McLeod, 2008). In a recent meta-analysis and pro-
spective cost-effectiveness study, Zhang et al. (2019) reported on 134 
studies of Chinese MMT programs published between 2004 and 2015. 
They concluded that the Chinese MMT programs were cost-effective, as 
negative behavior related to drug-related harm significantly decreased. 
Additionally, applying an estimation model, they calculated that $1037 
of MMT-related investment prevented about 29,463 new HIV infections, 
130,563 new HCV infections, and 10,783 deaths related to HIV, HCV 
and drug-related harm. Thus, MMT programs were highly effective in 
reducing HIV/AIDS and HCV epidemics and damaging drug-related 
behavior, in increasing the overall health of people living with HIV, 
and in avoiding other health problems in this group. Similarly, Karki 
et al. (2016), in their systematic review, concluded that MMT led to a 
dramatic drop in injected drug use, in sharing needles, in new cases of 
people with HIV, AIDS and HCV, and in commercial sex work. On the 
other hand, adherence of HIV sufferers to MMT programs remains a 
challenge. 
As regards the arrangements for methadone maintenance therapy in 
Iran, Bastani et al. (2019) noted that Iran has developed the most robust 
harm reduction infrastructure in the Middle East. Typically, 
low-threshold drop-in centers offer free sterile needles, syringes and 
condoms to between 170 and 230 thousand people who inject drugs. In 
addition, about 6000 MMT programs are delivering care to about half a 
million of people with OUD . In other countries, about 60% of those in 
the HIV and OUD categories and also undergoing MMT relapse and reuse 
drugs within the first three months (Zhang et al., 2019). High recidivism 
rates are also a major concern in Iran (Bastani et al., 2019; Pashaei et al., 
2013). Bastani et al. (2019) observed that social and structural barriers, 
and the use of other illicit drugs, particularly amphetamine-like drugs 
(see also Zhang et al., 2019), may be partly responsible for these rates. 
Pashaei et al. (2013) found that cognitive-behavioral interventions were 
effective in reducing relapse rates from 63.6% in a control condition to 
36.4% in an intervention condition. 
MMT also have disadvantages. Thus methadone in common with 
other opioids leads to altered sleep patterns; impaired sleep is already a 
major health problem for HIV sufferers (Gutierrez et al., 2019; Low 
et al., 2014; Hahmood et al., 2018; Patterson et al., 2019). Hahmood 
et al., 2018 observed that in HIV and opioid use disorder cases between 
56% and 73% had sleep-related issues; this compares to 10%–30% in the 
general population (Low et al., 2014). Patterson et al. (2019) reported 
that, compared to a healthy population, HIV sufferers were more likely 
to experience poor sleep. This high risk of poor sleep might be related to 
use of antiretroviral medication (for a contrary opinion see Hahmood 
et al., 2018 or to excessive tobacco use (Patterson et al., 2019), while a 
potentially life-long highly irregular sleep-wake pattern associated with 
a chaotic life style might also contribute to a generally poor sleep 
pattern. In the same vein, Gamaldo et al. (2013) argued that psychiatric 
and psychosocial issues such as symptoms of depression, perceived 
stress, social exclusion, and poverty also resulted in poor sleep. Likewise, 
Gutierrez et al. (2019) reported that, compared to a healthy population, 
up to 75% of HIV cases self-reported sleep disturbances. Typical in-
dicators were more fragmented sleep, reduced sleep efficiency, and a 
longer sleep onset latency. Furthermore, 20–95% of those with HIV re-
ported symptoms of insomnia, though it was unclear whether poor sleep 
in these cases meant sleep disturbances or insomnia or both (Low et al., 
2014). In the light of these observations the first aim of the present study 
was to improve the sleep of HIV patients undergoing MMT. To this end 
participants were assigned to one of three different interventions 
(trazodone (TRAZ); sleep hygiene training (SHT); sleep hygiene training 
+ trazodone (SHT + TRAZ; see details below). 
Suffering from HIV/AIDS and undergoing MMT is also related to an 
increased risk of sleep apnea (Gutierrez et al., 2019; Kunisaki et al., 
2015; Teichtahl and Wang, 2007; Wang and Teichtahl, 2007). Wang and 
Teichtahl (2007) estimated that up to 30% of HIV and OUD OUD cases 
suffer from central sleep apnea (CSA) (Wang et al., 2005), while 
obstructive sleep apneas (OSAs) may also be involved. As a general 
observation, opioids are respiration-depressing, leading to abnormal 
awake and ventilatory responses to hypercapnia and hypoxia. Wang and 
Teichtahl (2007) reported two findings. First, there is an association 
between higher CSA and higher methadone blood concentrations. Sec-
ond, imaging studies of HIV patients under long-term MMT showed 
structural brain damage, particularly in the mid brain of the brain stem, 
the location of the central respiratory controller. These results suggested 
that regular and long-term use of opioids such as methadone may harm 
those brain regions responsible for central respiratory functioning. In 
the light of these observations we asked whether sleep-improving in-
terventions could have a positive impact on subjective and self-rated 
dimension of OSAs. Therefore, the second aim of the present study 
was to investigate the influence of sleep-improving interventions on 
participants’ self-rated sleep-disordered breathing. 
As a general rule, restoring sleep is also associated with better 
cognitive functioning (Curcio et al., 2006; Devore et al., 2016; Killgore 
et al., 2008; Leong et al., 2019; Lo et al., 2016; Lowe et al., 2017; Van 
Dongen et al., 2003; Wardle-Pinkston et al., 2019; Wu et al., 2018). As 
regards those with HIV, Hahmood et al., 2018 showed in their experi-
mental study an association between sleep disturbances and poor 
cognitive performance. Byun et al. (2016) reported a similar pattern. 
Given this, the third aim of the present study was to investigate the 
extent of the relation between sleep and cognitive performance and 
whether improvements in sleep would be associated with improvements 
in working memory and sustained attention. 
Symptoms of depression are also associated with poor cognitive 
performance (Norell-Clarke et al., 2014; Sater et al., 2015), with poor 
sleep (Alvaro et al., 2013; Baglioni et al., 2010; Fava, 2004; Goldstein 
and Walker, 2014; Manber and Chambers, 2009; Nutt et al., 2008; 
Rumble et al., 2015) and with anxiety (Alvaro et al., 2013; Cox and 
Olatunji, 2016; Hertenstein et al., 2018). The fourth aim of the present 
study was therefore to determine whether interventions to improve 
sleep would also reduce symptoms of depression and anxiety. 
Next, HIV patients undergoing MMT have reported poor sleep, which 
was associated with higher daytime sleepiness (Low et al., 2014) and 
fatigue (Faraut et al., 2018). The fifth aim of the study was to investigate 
whether sleep-improving interventions would also result in reductions 
in daytime sleepiness. 
Studies including both healthy samples and individuals with major 
depressive disorders have shown poor sleep to be associated with higher 
cortisol concentrations (Hatzinger et al., 2008, 2012, 2010; Hori et al., 
2011) and lower brain-derived neurotrophic factor (BDNF) concentra-
tions (Mikoteit et al., 2019; Monteiro et al., 2017), while improvements 
in sleep have been associated with a downregulation of cortisol con-
centrations and an up-regulation of BDNF concentrations. Given these 
findings, the sixth aim of the study was to examine whether 
sleep-improving interventions would also have a positive impact on 
cortisol and BDNF. 
We examined three strategies for improving sleep, a pharmacological 
intervention (trazodone (TRAZ)), a psychoeducational intervention 
(sleep hygiene training (SHT), and the combination of these in-
terventions (SHT + TRAZ). 
Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) 
used to treat major depressive disorders and anxiety disorders. Given its 
sleep-inducing and sleep-stabilizing properties (Everitt et al., 2018), 
trazodone is also administered as a sleeping-promoting medication. 
Sleep hygiene training as a proxy for psychoeducational in-
terventions is proven to be effective (Åslund et al., 2018; Ballesio et al., 
2018; Chung et al., 2018; Murawski et al., 2018; Thakral et al., 2020; 
Trauer et al., 2015; van Straten et al., 2018). Gee et al. (2019) concluded 
from their systematic review and meta-analysis that sleep hygiene 
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training also has positive effects with respect to symptoms of depression. 
We employed a combination of sleep hygiene training and trazodone 
intake as the third strategy. 
To summarize, for those with HIV and OUD , MMT has proved to be 
an effective and harm-reducing intervention. However, people with HIV 
also have poor sleep, impaired cognitive performance, and symptoms of 
depression and anxiety. Both trazodone and sleep hygiene training have 
been shown to improve sleep characteristics. Given this, the main aim of 
the present study was to investigate the degree of positive effect of sleep- 
improving interventions (TRAZ, SHT; SHT + TRAZ) on sleep, daytime 
sleepiness, symptoms of depression and anxiety, cognitive performance 
and biomarkers in a sample of male HIV patients receiving MMT. 
Five hypotheses and one research questions were formulated. As a 
preliminary statement and given the lack of previous studies in this field 
and with these forms of sleep-improving interventions, we had no spe-
cific expectations as regards the relative superiority of trazodone, sleep 
hygiene training, or their combination. 
Following others (Gutierrez et al., 2019; Low et al., 2014; Hahmood 
et al., 2018; Patterson et al., 2019), our first hypothesis was that 
sleep-improving interventions would benefit subjective sleep in this 
patient group. 
Second, following others (Byun et al., 2016; Killgore, 2010; Leong 
et al., 2019; Hahmood et al., 2018; Wardle-Pinkston et al., 2019) we 
expected that these sleep-improving interventions would improve 
cognitive performance. 
Third, on the basis of previous research (Alvaro et al., 2013; Cox and 
Olatunji, 2016; Hertenstein et al., 2018; Nutt et al., 2008; Rumble et al., 
2015) we anticipated that the interventions would reduce symptoms of 
depression and anxiety. 
Fourth, following others (Byun et al., 2016; Faraut et al., 2018; Low 
et al., 2014), we hypothesized that the interventions would reduce 
daytime sleepiness. 
Fifth, based on previous research (Hatzinger et al., 2010; Hori et al., 
2011; Lemola et al., 2015; Mikoteit et al., 2019), we expected the in-
terventions to result in decreased cortisol concentrations and increased 
BDNF concentration. 
Finally, we examined whether the sleep-improving interventions 
would alter the symptoms of sleep apnea, as it appears that sleep apnea 
in this patient group is an issue of the central neuronal respiratory 
controller (Gutierrez et al., 2019; Teichtahl and Wang, 2007; Wang and 
Teichtahl, 2007; Wang et al., 2005). 
We believe that results from this study may be of clinical and prac-
tical importance given that restoring sleep is crucial for daily func-
tioning, and that this is also true for HIV patients undergoing MMT. 
2. Methods 
2.1. Study procedure 
Male outpatients with HIV and receiving MMT at the Mehr Sina 
Clinic of the Kermanshah University of Medical Sciences (KUMS; Ker-
manshah, Iran) were approached to participate at the study. Potential 
participants were informed about the study aims and the confidential 
data handling. Thereafter, they signed a written informed consent. 
Participants were randomly assigned to one of the following study 
conditions: administration of trazodone 50 mg/d (TRAZ), sleep hygiene 
training (SHT); sleep hygiene + 50 mg/d trazodone (SHT + TRAZ). At 
the beginning of the study (baseline), after six weeks and then after 12 
weeks, participants completed questionnaires on sleep and sleep-related 
dimensions, and on symptoms of depression and anxiety. In parallel, we 
ran objective tests of participants’ cognitive performance (verbal 
working memory; sustained attention). At baseline and at the end of the 
study blood samples were taken to assess the following biomarkers: 
Cortisol, BDNF, and CD4+. 
The Ethical Committee of the Kermanshah University of Medical 
Sciences (ethics committee reference number: kums.rec.1395.255) 
approved the study, which was performed in accordance with the sev-
enth revision of the Declaration of Helsinki (World Medical Association, 
2013). The study was registered at the Iranian Register for Clinical Trials 
(itct.ir: IRCT2016110923705N8). 
2.2. Samples 
Fig. 1 presents the flow chart for participants’ recruitment and study 
condition assignments. 
A total of 130 possible participants were approached. Of these 55 
(42.31%) were excluded: Either they did not fulfill the inclusion criteria 
(see below) or they declined to participate. Seventy-five participants 
were assigned to one of the three study conditions (see below). 
In the TRAZ condition (N = 25), one participant dropped out after 
allocation, two had dropped by week 6, and three had dropped by week 
12; thus 19 participants in this condition completed the study. In the 
SHT condition (N = 25), two dropped out after allocation, five dropped 
by week 6, and seven dropped by week 12; thus, 11 of these participants 
completed the study. In the SHT + TRAZ condition (N = 25), three 
dropped out after allocation, two dropped out by week 6, and four 
dropped out by week 12; thus 16 of these participants completed the 
study. Overall, 46 (61.3%) of the original 75 participants completed the 
study. 
2.3. Randomization 
As in previous studies (Farnia et al., 2019; Jahangard et al., 2018), 
randomization was accomplished using the software randomization. 
com to create a list to assign 75 participants randomly to one of the 
three study conditions. Thereafter, a psychologist not otherwise 
involved in the study managed the assignments. 
2.4. Sample size calculation 
The sample size calculation was performed with G*Power® (Faul 
et al., 2007). Based on previous results (Hahmood et al., 2018), the 
following parameters were defined: effect size: 0.18 (Cohen’s f for 
ANOVAs); alpha error probability: 0.05; power: 0.80; number of groups: 
3; number of measurements: 3. These parameters give a total sample size 
of 66. However, to allow for drop-outs, the sample size was set at 75 
participants. 
2.5. Methadone maintenance therapy 
All patients were in receipt of methadone weekly at therapeutic 
dosages (mean: 40mg/w; see also (Farnia et al., 2019). 
2.6. Trazodone medication 
Participants in the TRAZ and SHT + TRAZ condition took trazodone 
50 mg/d every morning throughout the study. 
2.7. Sleep hygiene training 
A clinical psychologist experienced in sleep hygiene education pro-
vided sleep hygiene training in small groups of eight to ten participants. 
Training took place once a week for 50–60 min at the Mehr Sina Clinic. 
Basic topics were: “What is a normal sleep schedule?”, “Why is it 
important to have a regular sleep schedule?”; “Which techniques help us 
to maintain a stable sleep schedule, to fall asleep and to feel more 
refreshed in the morning?”; “Dos and Don’ts before going to sleep”; 
“How to get rid of “bad” thoughts to fall asleep”; and similar. Topics 
were discussed, solutions were elaborated, and sleep-improving tech-
niques were practiced during the sessions. Additionally, participants 
were encouraged to keep a sleep log and to exercise relaxation tech-
niques at home, though “home work” was not explicitly checked to 
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avoid drop-out through feelings of shame, insecurity or being overly 
supervised. 
2.8. Tools 
2.8.1. Sociodemographic, anthropometric, and illness-related information 
Participants reported on their age (in years), socioeconomic status 
(low; medium; high), civil status (single; married; divorced), highest 
educational level (compulsory school; high school; diploma; higher 
diploma), employment status (yes; no) and substance use (opioids; 
opioids + stimulants; opioids + hallucinogens). The following anthro-
pometric variables were measured: waist circumference (cm), neck 
circumference (cm); BMI (kg/m2). The following illness-related infor-
mation was taken from the most recently available medical records: 
duration of HIV diagnosis (years); age at commencement of methadone 
treatment (years); duration of methadone treatment (years); duration of 
substance use (years). 
2.8.2. Sleep and daytime sleepiness 
2.8.2.1. Subjective sleep: Pittsburgh Sleep Quality Index (PSQI (Buysse 
et al., 1989). The PSQI is a self-report scale that is completed in 5 min. It 
consists of 19 items and contains seven subscales (subjective sleep 
quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, 
sleeping medication, daytime dysfunction), each weighted equally on a 
scale from 0 to 3, with higher scores indicating poorer sleep quality. The 
seven components are then summed to obtain an overall PSQI score, 
ranging from 0 (good sleep quality) to 21 (poor sleep quality). Total 
scores of ≥5 reflect poor sleep, associated with considerable sleep 
complaints. Farrahi et al. (2012) have validated the psychometric 
properties of the Farsi version (Cronbach’s alpha = .85). 
2.8.2.2. Symptoms of insomnia. Subjective insomnia was assessed with 
the Insomnia Severity Index (ISI; Bastien et al., 2001; Gerber et al., 
2016). This questionnaire is a seven-item screening measure for 
insomnia. The items, answered on 5-point Likert scales ranging from 
0 (=not at all) to 4 (=very much), refer in part to the Diagnostic and 
Statistical Manual of Mental Disorders (American Psychiatric Associa-
tion, 2013) criteria for insomnia by assessing difficulty falling asleep, 
difficulty remaining asleep, early morning awakenings, impaired day-
time performance, low satisfaction with sleep, and worry about sleep. 
The higher the overall score, the more the participant is assumed to 
suffer from insomnia (Cronbach’s alpha = 0.89). 
2.8.2.3. Daytime sleepiness. To assess daytime sleepiness, participants 
completed the Epworth Sleepiness Scale (ESS; (Johns, 1991), which 
consists of ten items rating the odds of dozing off during different ac-
tivities. Answers are given on 4-point rating scales (0–3), with higher 
sum scores reflecting greater daytime sleepiness. The sum score ranges 
from 0 to 30 points; a global score greater than 10 indicates excessive 
daytime sleepiness. ESS scores were treated as continuous. The Cron-
bach’s α for the present sample was 0.89. 
Fig. 1. CONSORT diagram showing the flow of participants through each stage.  
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2.8.2.4. Sleep-disordered breathing. The Berlin Questionnaire (Netzer 
et al., 1999) is a self-rating questionnaire designed to assess risk of 
suffering from Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS). 
The items are as follows. Category 1: 1. “Do you snore?” (yes/no/I don’t 
know); 2. “Your snoring is …” (as loud as normal breathing/as loud as 
talking/louder than talking); 3. “How often do you snore?” (almost 
every day/3–4 times a week/1–2 times a week/1–2 times a month/-
rarely or never). 4. Has your snoring ever bothered other people?” 
(yes/no/I don’t know); 5. Has anyone noticed that you stop breathing 
during sleep?” (almost every day/3–4 times a week/1–2 times a 
week/1–2 times a month/rarely or never). Category 2: 6. “How often do 
you feel tired or fatigued after your sleep?” (almost every day/3–4 times 
a week/1–2 times a week/1–2 times a month/rarely or never). 7. 
“During your waking time, do you feel tired, fatigued or not up to par?” 
(almost every day/3–4 times a week/1–2 times a week/1–2 times a 
month/rarely or never). 8. “Have you ever nodded off or fallen asleep 
while driving a vehicle?” (yes/no). If your answer is ‘yes’; 9. How often 
does it occur? (almost every day/3–4 times a week/1–2 times a 
week/1–2 times a month/rarely or never). Category 3: 10. “Do you have 
high blood pressure?” (yes/no/I don’t know). High risk for Obstructive 
Sleep Apnea/Hypopnea Syndrome (OSAHS) is taken to exist when there 
are persistent symptoms (more than three or four times per week) in 
categories 1 and 2, and hypertension (P140/90 mmHg or use of medi-
cation) or BMI P30 kg/m2 in category 3. Categories 1 and 2 are positive 
when the sum of all items is 2. Individuals are classified as having high 
risk for OSAHS if scores are positive in two or more categories. In-
dividuals scoring positive in only one or none of the categories are 
classified as low risk. The sum score was treated as a continuous 
variable. 
2.9. Self-report of depressive symptoms: Beck Depression Inventory (BDI) 
Participants completed the Beck Depression Inventory (Beck et al., 
1961) Farsi version (for psychometric properties of the Farsi version see 
(Ghassemzadeh et al., 2005). This inventory samples self-reported 
symptoms of depression. The questionnaire consists of 21 items and 
asks about different aspects such as depressive mood, loss of appetite, 
sleep disorders, suicidality and similar. Each question has a set of at least 
four possible responses, ranging in intensity; e.g., ‘sadness’: 0 = ‘I do not 
feel sad’; 1 = ‘I feel sad’; 2 = ‘I am sad all the time and I can’t snap out of 
it’; 3 = ‘I am so sad or unhappy that I can’t stand it.’, and with higher 
scores reflecting greater severity of depressive symptoms (Cronbach’s 
alpha = .89). 
2.10. Self-report of symptoms of anxiety 
Symptoms of anxiety were assessed with the Beck Anxiety Inventory 
(BAI; Beck et al., 1988). Hossein Kaviani and Mousavi (2008) have re-
ported robust and reliable psychometric properties for the Farsi version 
of this inventory. The BAI consists of 21 items addressing typical 
cognitive, emotional and bodily signs of anxiety such a fear of the worst 
happening, numbness and tingling, or sweating not due to heat. Answers 
are given on 4-point rating scales with the anchor points 0 (= not at all) 
and 3 (= severely/it bothers me a lot), and with higher sum scores 
reflecting more marked symptoms of anxiety (Cronbach’s alpha = 0.81). 
Respondents were categorized as follows (Hossein Kaviani and Mousavi, 
2008; Beck et al., 1988): 0–9: minimal anxiety; 10–16: mild anxiety; 
17–29: moderate anxiety; 30–63: severe anxiety. 
2.11. Cognitive testing 
2.11.1. Verbal working memory 
The Digit Span subtest of the Wechsler Adult Intelligence Scale 
(WAIS-IV; Wechsler, 2008) was administered to assess verbal working 
memory. This task has two conditions. In the forward condition, se-
quences of digits of increasing length have to be repeated in the same 
order as presented. In the backward condition, digit sequences have to 
be repeated in reverse order. 
2.11.2. Sustained attention 
To assess sustained attention, we employed the d2-test (Brick-
enkamp, 2002). The test consists of the following tasks. There are 14 
lines consisting of symbols. Symbols may be d or p with no, one, two, 
three or four small lines. The participant must mark within 20sec as 
many as possible of the symbols consisting of a d and two small lines. 
Crossing a d with two small lines equals a correct answer; crossing a 
d with one, three or four lines, or crossing a p, or missing a d with two 
lines are all treated as errors. In the present study, we considered only 
the correct responses. 
2.12. Cortisol, BDNF, CD4+
At the beginning and 12 weeks later, participants’ blood samples 
were taken at 8am on an empty stomach. Blood sampling was performed 
intravenously from the inner fold of the elbow, though in some partic-
ipants due to a lack of accessible blood vessels in this location blood 
samples were taken from the back of the hand or foot. 
All blood samples were sent to Farabi Hospital Laboratory of the 
Kermanshah University of Medical Sciences (Kermanshah, Iran) and 
serum was isolated by a centrifugal device. All serums were stored until 
completion of the study at − 20 ◦C in a special refrigerator for storage of 
biomarkers in the Sleep Disorders Research Center (KUMS; Kermanshah, 
Iran). 
Enzyme-linked immune sorbent assay (ELISA) kits based on the 
Biotin double antibody sandwich technology were employed to assay 
the Human Cluster Of differentiation4 (CD4), Human Cortisol, and 
Brain-Derived Neurotrophic Factor (BDNF). Cortisol and BDNF ELISA 
kits were produced by Biston Teb Company (Kermanshah, Iran) on 
behalf of Zell Bio GmbH (Germany), while the CD4 ELISA kit was pro-
vided by Tarvand Sina Headquarters Company (Esfahan, Iran) on behalf 
of EASTBIOPHARM (USA). All cortisol, BDNF, and CD4+ analyses were 
performed in the laboratory of Imam Reza Clinic (Kermanshah, Iran). 
Further information on detailed laboratory analyses are available as 
supplementary files. 
2.13. Statistical analysis 
Statistical analyses were not performed per protocol, but by intent- 
to-treat, with the last observation carried forward (LOCF) method. 
The primary outcome variables were sleep related. These included 
sleep quality and sleep quantity (Pittsburgh Sleep Quality Index), 
symptoms of insomnia (Insomnia Severity Index), daytime sleepiness 
(Epworth Sleepiness Scale), sleep disordered breathing (Berlin 
questionnaire). 
Secondary outcome variables were psychological and cognitive di-
mensions and physiological biomarkers.  
a) Psychological dimensions: Symptoms of depression as assessed by 
the Beck Depression Inventory; symptoms of anxiety as assessed by 
the Beck Anxiety Inventory  
b) Cognitive dimensions: Working memory (digit span forward and 
backward); measure of selective and sustained attention and visual 
scanning speed from the d2-test.  
c) Physiological markers: Cortisol; BDNF, CD4+. 
Differences across treatment conditions in age and duration of illness 
were assessed via one-way ANOVAs. A series of ANOVAs for repeated 
measures was performed with the following factors: Group (TRAZ; SHT; 
SHT + TRAZ) and Time (baseline; week 6; week 12); dependent vari-
ables were sleep quality (PSQI), symptoms of insomnia (ISI), daytime 
sleepiness (ESS), sleep-disordered breathing (Berlin); depression (BDI), 
anxiety (BAI): working memory (digit span forward and backward), 
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sustained attention (d2). For physiological dimensions the factor Time 
had two values (baseline; week 12); dependent variables were: cortisol-, 
BDNF-, and CD4+ levels. In case of deviation from sphericity, ANOVAs 
were computed using Greenhouse-Geisser corrected degrees of freedom, 
though the original degrees of freedom are reported with the relevant 
Greenhouse-Geisser epsilon value (ε). 
For ANOVAs, effect sizes are reported as partial eta squared (ηp2), 
with 0.01 < ηp2 < 0.059 indicating small [S], 0.06 < ηp2 < 0.139 indi-
cating medium [M], and ηp2 > 0.14 indicating large [L] effect sizes. 
All statistical computations were performed with SPSS® 25.0 (IBM 
Corporation, Armonk NY, USA) for Apple Mac®. 
3. Results 
3.1. Sociodemographic and illness-related information 
Table 1 provides the descriptive and inferential statistical indices for 
age and HIV-related information for the three conditions. These indices 
are not repeated in the text. 
No descriptive or statistically significant differences were found be-
tween the three groups (TRAZ, SHT, SHT + TRAZ) as regards age, BMI, 
waist circumference, neck circumference, duration of the HIV diagnosis, 
age at methadone treatment onset, duration of methadone treatment, 
duration of substance use, socioeconomic status, civil status, highest 
educational level or type of substance use. 
3.2. Subjective sleep parameters (PSQI; ISI, ESS), over time (baseline, 
week 6, week 12) and between and within groups (TRAZ, SHT; SHT +
TRAZ) 
Table 2 provides a descriptive statistical overview, while Table 3 
provides the inferential statistical overview for the dimensions of sleep 
over time and across the three groups. These indices are not repeated in 
the text. 
3.2.1. Pittsburgh Sleep Quality Index 
No significant or descriptive mean differences were observed over 
time or between groups for sleep latency, sleep efficiency, sleep medi-
cation or sleep quality. 
There was a significant between-group difference in sleep duration; 
post-hoc analyses with Bonferroni-Holm corrections for p-values 
showed that sleep duration improved significantly in the SHT + TRAZ 
condition. 
Sleep disturbances significantly decreased over time, but not be-
tween groups. However, post-hoc analyses with Bonferroni-Holm cor-
rections for p-values showed that sleep disturbances decreased 
significantly from baseline to week 6 in both SHT and SHT + TRAZ 
conditions (see Fig. 2). 
Daytime dysfunction significantly decreased over time, but not be-
tween groups. However, post-hoc analyses with Bonferroni-Holm cor-
rections for p-values showed that sleep disturbances decreased 
significantly from baseline to week 6 in the SHT and SHT + TRAZ 
conditions (see Fig. 3). Furthermore, daytime dysfunction remained low 
across time in the SHT + TRAZ condition. 
The Pittsburgh Sleep Quality Index overall scores decreased signifi-
cantly over time, but without differences between groups (see Fig. 4). 
3.3. Insomnia (ISI) and daytime sleepiness (ESS) 
There were no significant or descriptive mean differences over time 
or between groups in these variables. 
3.4. Self-rated symptoms of depression and anxiety 
Tables 4 and 5 provide the descriptive and inferential statistical 
indices of self-rated symptoms of depression and anxiety separately for 
the three time points and for the three groups. 
Symptoms of depression and anxiety reduced over time; there was no 
group or time by group-interaction effect. Post-hoc analyses with 
Bonferroni-Holm corrections for p-values showed that symptoms of 
depression and anxiety decreased from baseline to week 6, and there-
after remained unchanged. 
3.5. Working memory (digit span forward and backward) and sustained 
attention (d2-test) 
Tables 6 and 7 provide the descriptive and inferential statistical 
overview of cognitive performance scores for working memory (digit 
span forward and backward) and sustained attention (d2-test). 
For working memory, the performance for digit span forward did not 
Table 1 
Descriptive and statistical overview of sociodemographic variables separately by treatment condition.   
Groups  
Trazodone Sleep hygiene 
training 
Trazodone + sleep hygiene 
training 
Statistics 
N 24 23 22   
M (SD) M (SD) M (SD)  
Age (years) 37.71 (6.38) 39.78 (6.26) 41.27 (6.44) F(2, 66) = 1.82 
BMI 21.24 (3.30) 21.77 (2.40) 2.50 (2.75) F(2, 66) = 1.13 
Waist circumference (cm) 74.75 
(17.51) 
69.17 (16.85) 70.00 (16.83) F(2, 66) = 0.73 
Neck circumference (cm) 36.37 (2.89) 38.21 (5.35) 35.22 (7.99) F(2, 66) = 1.57 
Duration of HIV diagnosis (years) 12.29 (7.48) 13.82 (7.73) 15.04 (6.24) F(2, 66) = 0.85 
Age at methadone treatment (years) 30.50 (7.08) 30.57 (8.93) 33.91 (8.53) F(2, 66) = 1.27 
Duration of methadone treatment (years) 9.38 (16.21) 9.61 (7.65) 8.18 (6.64) F(2, 66) = 0.10 
Duration substance use (years) 16.46 (5.97) 19.13 (7.86) 18.14 (9.25) F(2, 66) = 0.71   
n/n/n n/n/n n/n/n  
Socioeconomic status (low/medium/high) 13/11/0 17/6/0 17/5/0 X2(N = 69, df = 4) = 1.06 
Civil status (single/married/divorced) 10/9/4 9/10/4 12/10/0 X2(N = 69, df = 4) = 8.58 
Highest educational level (compulsory school/high school/diploma/high 
diploma) 
3/8/12/1 6/3/13/1 8/2/11/1 X2(N = 69, df = 6) =
11.16 
Occupation (yes/no) 22/11 17/16 20/13 X2(N = 69, df = 2) = 1.72 
Substance use (opium/opium + stimulants/opium + hallucinogens) 15/6/3 11/8/4 15/4/3 X2(N = 69, df = 4) = 2.26  
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Table 2 
Descriptive overview of sleep dimensions (Pittsburgh Sleep Quality Index; Insomnia Severity Index; Epworth Sleepiness Scale; Berlin questionnaire), separately by 
assessment time (baseline, week 6, week 12), and group (trazodone; sleep hygiene training; trazodone + sleep hygiene training).   
Assessment times 
Baseline Week 6 Week 12 
TRAZ SHT SHT + TRAZ TRAZ SHT SHT + TRAZ TRAZ SHT SHT + TRAZ 
N 24 23 22 22 18 20 19 11 16 
Pittsburgh Sleep Quality 
Index 
M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) M (SD) 
Sleep latency 3.21 (1.67) 3.39 (1.75) 2.90 (2.14) 3.17 (1.55) 3.09 (1.62) 2.50 (1.74) 2.75 (1.67) 3.30 (1.72) 3.09(1.85) 
Sleep duration 1.12 (1.03) 1.65 (1.11) 1.27 (1.12) 0.95 (0.81) 1.61 (0.94) 1.09 (1.06) 1.00 (0.83) 1.35 (0.83) 1.04 (0.90) 


















Sleep disturbances 10.71 (4.47) 11.04 (4.30) 11.14 (4.84) 9.96 (4.48) 8.78 (4.18) 9.09 (4.83) 9.62 (4.70) 8.70 (4.64) 9.40 (5.40) 
Sleep medications 1.37 (1.24) 1.26 (1.10) 0.81 (0.91) 1.50 (1.32) 1.17 (1.37) 0.81 (1.18) 1.25 (1.26) 1.21 (1.28) 0.73 (1.12) 
Daytime dysfunction 2.57 (1.65) 2.86 (1.93) 2.29 (1.85) 2.00 (1.51) 1.81 (1.26) 2.12 (1.57) 2.17 (1.56) 1.77 (1.11) 2.05 (1.77) 
Subjective sleep quality 1.58 (0.97) 1.87 (0.87) 1.41 (1.05) 1.25 (0.90) 1.70(0.82) 1.50(0.86) 1.33 (0.96) 1.70 (0.76) 1.68 (0.84) 
PSQI overall score 10.41 (3.28) 10.70 (3.02) 9.45 (4.69) 9.37 (3.24) 9.78 (3.10) 8.18 (3.25) 9.00 (3.78) 9.38 (3.41) 8.25 (3.26)  
Insomnia Severity Index 12.79 (5.96) 13.60 
(60.61) 
13.59 (6.56) 11.21 (4.75) 13.78 (4.47) 12.86 (5.86) 12.17 (5.00) 13.87(4.99) 11.77 (6.42) 
Epworth Sleepiness scale 5.92 (4.96) 4.87 (4.14) 6.09 (4.45) 6.37 (3.98) 4.74 (4.22) 6.72 (4.62) 5.58 (4.36) 4.35 (3.50) 6.90 (4.52) 
Berlin 1.96 (1.78) 1.91 (1.90) 1.95 (1.49) 1.83 (1.52) 1.52 (1.80) 1.77 (1.51) 1.46 (1.28) 1.35 (1.80) 2.04 (2.10) 
Notes: TRAZ=trazodone ; SHT = sleep hygiene training ; SHT + TRAZ : sleep hygiene training + trazodone; PSQI = Pittsburgh Sleep Quality Inventory. 
Table 3 
Descriptive and inferential statistical indices of physiological scores.   
Inferential statistics 
Time Group Time × Group interaction Greenhouse-Geisser ε 
F η2p  [ES] F η2p  [ES] F η2p  [ES]  
Pittsburgh Sleep Quality Index 
Sleep latency F(1, 61) = 0.56 0.008 [S] F(2, 61) = 0.58 0.017 [S] F(2, 61) = 0.79 0.023 [S] 0.92 
Sleep duration F(1, 61) = 1.44 0.021 [S] F(2, 61) = 3.04* 0.085 [M] F(2, 61) = 0.70 0.021 [S] 0.95 
Sleep efficiency F(1, 61) = 2.32 0.034 [S] F(2, 61) = 0.19 0.006 [S] F(2, 61) = 0.37 0.011 [T] 0.88 
Sleep disturbances F(1, 61) = 5.41** 0.076 [M] F(2, 61) = 0.038 0.001 [S] F(2, 61) = 0.39 0.012 [T] 0.98 
Sleep medications F(1, 61) = 0.24 0.004 [T] F(2, 61) = 2.33 0.066 [S] F(2, 61) = 0.16 0.005 [T] 1.00 
Daytime dysfunction F(1, 61) = 4.83** 0.068 [M] F(2, 61) = 0.12 0.004 [S] F(2, 61) = 0.25 0.008 [T] 0.95 
Subjective sleep quality F(1, 61) = 0.72 0.011 [T] F(2, 61) = 1.60 0.20 [S] F(2, 61) = 1.08 0.032 [S] 0.94 
PSQI overall score F(1, 61) = 4.42* 0.063 [M] F(2, 61) = 1.40 0.041 [M] F(2, 61) = 0.13 0.004 [T] 0.96 
Insomnia Severity Index F(1, 61) = 0.72 0.001 [T] F(2, 61) = 0.80 0.024 [S] F(2, 61) = 0.68 0.020 [S] 0.97 
Epworth Sleepiness scale F(1, 61) = 0.33 0.005 [T] F(2, 61) = 1.59 0.046 [S] F(2, 61) = 0.46 0.014 [T] 0.93 
Berlin F(1, 61) = 1.70 0.025 [S] F(2, 61) = 0.28 0.009 [S] F(2, 61) = 0.87 0.026 [S] 0.95 
Notes: * = p < .05; ** = p < .01; [S] = small effect size; [M] = medium effect size. 
Fig. 2. Sleep disturbances over time and between groups. Points are means. A lower score reflects fewer sleep disturbances. TRAZ = trazodone (n = 19); SHT = sleep 
hygiene training (n = 11); SHT + TRAZ = sleep hygiene training + trazodone (n = 16). 
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differ across time or between groups. 
For the more difficult task of backward digit span performance 
declined over time in all groups. 
For sustained attention (d2-test; correct items), performance 
improved over time, irrespective of group. Post-hoc analyses after 
Bonferroni-Holm corrections for p-values showed that performance 
improved from baseline to week 6 but remained unchanged from week 6 
to week 12. 
Fig. 3. Daytime dysfunction over time and between groups. Points are means. A lower score reflects lower daytime dysfunction. TRAZ = trazodone (n = 19); SHT =
sleep hygiene training (n = 11); SHT + TRAZ = sleep hygiene training + trazodone (n = 16). 
Fig. 4. Overall scores over time and between groups. Points are means. A lower score reflects a lower daytime dysfunction. TRAZ = trazodone (n = 19); SHT = sleep 
hygiene training (n = 11); SHT + TRAZ = sleep hygiene training + trazodone (n = 16). 
Table 4 
Descriptive overview of depression and anxiety scores, separately by assessment time (baseline; week 6; week 12), and group (trazodone; sleep hygiene training; 
trazodone + sleep hygiene training).   
Assessment times 
Baseline Week 6 Week 12 
TRAZ SHT SHT + TRAZ TRAZ SHT SHT + TRAZ TRAZ SHT SHT + TRAZ 
N 24 23 22 22 18 20 19 11 16  
M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) 
Depression 17.08 (6.74) 17.30 (7.74) 17.09 (9.72) 15.16 (8.96) 16.39 (10.60) 15.54 (9.62) 15.50 (8.43) 14.65 (10.61) 15.59 (7.53) 
Anxiety 24.54 (12.15) 25.26 (11.69) 24.63 (15.33) 21.83 (12.57) 20.78 (11.73) 19.77 (10.43) 25.12 (13.42) 21.60 (12.79) 19.90 (12.30) 
Notes: TRAZ = trazodone; SHT = sleep hygiene training; SHT + TRAZ = sleep hygiene training + trazodone. 
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3.6. Biomarkers 
Table 8 provides the descriptive and inferential statistical indices for 
the biomarkers cortisol, BDNF, and CD4+ for the three groups (TRAZ, 
SHT, SHT+TRAZ SHT) and for the two assessment time points (baseline; 
week 12). 
Cortisol, BDNF and CD4+ did not change significantly or descrip-
tively over time, between the groups, or between groups over time 
(interaction effect). 
4. Discussion 
The key findings of the present study were that among a sample of 
males with HIV and opioid use disorder and undergoing regular meth-
adone maintenance therapy, sleep-improving interventions had positive 
effects on aspects of self-reported sleep, symptoms of depression and 
anxiety, and cognitive performance. More specifically and compared to 
treatment with trazodone alone (TRAZ), sleep hygiene training (SHT) 
and the combination of sleep hygiene training and trazodone (SHT +
Table 5 
Descriptive and inferential statistical indices of symptoms of depression and anxiety.   
Factors  
Time Group Time × Group interaction Greenhouse-Geisser 
F η2p  [EF] F η2p  [EF] F η2p  [EF] ε 
Depression F(2, 132) = 3.10* 0.045 [S] F(2, 66) = 0.04 0.001 [T] F(4, 121) = 0.33 0.010 [T] 0.94 
Anxiety F(2, 132) = 4.56* 0.065 [M] F(2, 66) = 0.28 0.009 [T] F(4, 132) = 0.74 0.022 [S] 0.94 
Notes: * = p < 0.05; EF = effect size; T = trivial effect size S = small effect size, M = medium effect size. 
Table 6 
Descriptive overview of cognitive performance scores, separately by assessment time (baseline, week 6, week 12), and group (trazodone; sleep hygiene training; 
trazodone + sleep hygiene training).    
Assessment times 
Baseline Week 6 Week 12 
TRAZ SHT SHT + TRAZ TRAZ SHT SHT + TRAZ TRAZ SHT SHT + TRAZ 
N 24 23 22 22 18 20  19 11 
Cognitive 
performance 
M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) M(SD) 


















Digit span forward 5.00 (1.72) 5.13 (1.79) 5.13 (1.64) 5.66 (1.66) 4.74 (2.02) 5.54 (1.94) 5.66 (1.55) 5.04 (1.87) 5.72 (1.93) 
Digit span backward 4.75 (1.35) 4.30 (1.32) 4.81 (1.53) 4.16 (1.04) 4.04 (1.26) 4.31 (1.35) 4.25 (0.99) 3.87 (1.29) 4.45 (1.56) 
Notes: TRAZ = trazodone; SHT = sleep hygiene training; SHT + TRAZ = sleep hygiene training + trazodone. 
Table 7 
Descriptive and inferential statistical indices of cognitive performance scores.   
Factors  
Time Group Time × Group interaction Greenhouse-Geisser 
Cognitive performance F η2p  [ES] F η2p  [ES] F η2p  [ES] ε 
d2 (correct answers) F(1, 64) = 10.80** 0.14 [L] F(2, 66) = 1.45 0.044 [S] F(2, 64) = 1.11 0.034 [S] 1.00 
Digit span forward F(2, 132) = 1.86 0.027 [S] F(2, 66) = 0.79 0.023 [S] F(4, 132) = 1.36 0.040 [S] 0.95 
Digit span backward F(2, 132) = 4.95** 0.070 [M] F(2, 66) = 1.11 .033 [S] F(4, 121) = 0.25 0.008 [S] 0.98 
Notes: ** = p < .01; S = small effect size, M = medium effect size; L = large effect size. 
Table 8 
Descriptive and inferential statistical indices of physiological scores.   
Groups Inferential statistics 
Baseline Study end  
TRAZ SHT SHT +
TRAZ 
TRAZ SHT SHT +
TRAZ 
Time Group Time × Group interaction 
N 24 23 22 19 11 16           















.028 [S] F(2, 61) 
= 0.15 

















.001 [T] F(2, 61) 
= 0.03 

















.001 [T] F(2, 61) 
= 0.49 
.016 [T] F(2, 61) 
= 0.22 
.007 [T] 
Notes: TRAZ = trazodone; SHT = sleep hygiene training; SHT + TRAZ: sleep hygiene training + trazodone. 
BDNF = brain derived neurotrophic factor; CD4+ = cluster of differentiation 4. T = trivial effect size; S = small effect size. 
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TRAZ) led to observable improvements after six weeks and these im-
provements were sustained for a further six weeks. Thus, it appeared 
that SHT (stand alone or in combination with TRAZ) led to improve-
ments in sleep and affect, while all three interventions had positive ef-
fects on cognitive performance. We therefore believe that the present 
results add to the current literature in an important way; the results are 
of clinical and practical importance, because they show that sleep- 
promoting interventions are both feasible and beneficial for those with 
HIV and OUD and undergoing MMT. 
Five hypotheses and one research question were formulated and each 
of these is considered in turn. 
Our first hypothesis was that sleep-improving interventions would 
enhance subjective sleep among male HIV patients undergoing MMT, 
and this hypothesis was generally supported. Over time, sleep distur-
bances decreased, and both sleep quality and daytime functioning 
improved. In these respects the present findings accord with previous 
studies (Gutierrez et al., 2019; Low et al., 2014; Hahmood et al., 2018; 
Patterson et al., 2019). However, we expand upon this previous work in 
showing that sleep hygiene training (SHT) in particular had positive 
effects. Compared to administration of TRAZ alone, SHT and SHT +
TRAZ reduced sleep disturbances and improved sleep quality, along 
with daytime functioning, within six weeks of their introduction and 
sustained these improvements for a further six weeks. The evidence 
available from the study is unable to shed direct light on the psycho-
logical and physiological mechanisms that might explain these im-
provements, though we consider some possibilities below. 
Our second hypothesis was that sleep-promoting interventions 
would improve cognitive performance, and this was supported for sus-
tained attention, but not for working memory. Nevertheless, our find-
ings are consistent with other research (Byun et al., 2016; Killgore, 
2010; Leong et al., 2019; Hahmood et al., 2018; Wardle-Pinkston et al., 
2019), but go further in that the improvements were found irrespective 
of the type of sleep-promoting intervention. Unfortunately, again we 
cannot draw any direct conclusions about psychophysiological mecha-
nisms that might underlie these effects and the fact that sustained 
attention improved but working memory did not is an added compli-
cation. For want of direct evidence, the following admittedly speculative 
possibilities are advanced. First, it may be that improvement in sus-
tained attention occurred as a consequence of improved daytime func-
tioning and improved sleep quality. However, this possibility does not 
explain, why there was no improvement in working memory. Second, it 
is possible that improvements in sustained attention were epiphe-
nomena of training effects, though such effects have not so far been 
found for the d2-test (Brickenkamp, 2002) while training effects should 
also have occurred for working memory. Third, the outcome variable for 
the d2-test was the sum of correct items within a set time; incorrect 
answers were not scored. Taking incorrect answers into consideration 
might have produced another pattern of results. 
Our third hypothesis was that sleep-improving interventions would 
reduce symptoms of depression and anxiety, and this was fully sup-
ported. Thus, while the present findings replicate other work (Alvaro 
et al., 2013; Cox and Olatunji, 2016; Hertenstein et al., 2018; Nutt et al., 
2008; Rumble et al., 2015), for the following reasons they also take 
matters further. First, these improvements were obtained with a patient 
group not previously studied in this way. Second, the improvements 
were observable within six weeks of initiating treatment, and third they 
were sustained for a further six weeks. Gee et al. (2019) found from their 
systematic review and meta-analysis that non-pharmacological sleep 
interventions reduced symptoms of depression. However, it is not sur-
prising that there were reductions in symptoms of both depression and 
anxiety. Transdiagnostic psychotherapy (Norton et al., 2013; Norton 
and Paulus, 2016; Norton and Roberge, 2017; Pearl and Norton, 2017) is 
based on propositions that cognitive-emotional improvements are not 
diagnosis-specific, that there is a substantial overlap in symptoms of 
depression and anxiety, and that improvements on one dimension (e.g., 
depression) will therefore be accompanied by improvements on another 
(e.g., anxiety). 
Our fourth hypothesis was that sleep-improving interventions would 
reduce daytime sleepiness, but this was not supported. Thus, our find-
ings here do not match those from previous research (Byun et al., 2016; 
Faraut et al., 2018; Low et al., 2014). In this context, we also found no 
improvement in insomnia scores. The following are possible reasons for 
the lack of effects here. First, the tools might be too coarse-grained to 
detect subtle changes. Second, participants may have had difficulties 
distinguishing between daytime sleepiness and fatigue. Third, there was 
really no change in daytime sleepiness. 
Our fifth hypothesis was that sleep-improving interventions would 
decrease cortisol concentration and increase BDNF concentration but 
this was not supported. Again, therefore, our results do not match pre-
vious findings (Hatzinger et al., 2010; Hori et al., 2011; Lemola et al., 
2015; Mikoteit et al., 2019). The following are possible explanations for 
our failure to find these effects. First, the physiological condition of 
males with HIV and OUD and undergoing MMT might be too deterio-
rated for a 12-week intervention to produce any improvement. Second, 
it is in the nature of the psychology-physiology-trade-off that changes on 
a cognitive-emotional level will not necessarily be associated with 
observable changes at a physiological level. This pattern has been 
observed for individuals with major depressive disorders and undergo-
ing ECT and physical activity exercise; Salehi et al. (2016) found that 
although symptom severity reduced following interventions, these 
cognitive-emotional improvements were entirely unrelated to changes 
in BDNF concentrations. Similarly, Gerber et al. (2016) reported that for 
individuals with major depressive disorders, improvements on a 
non-pharmacological stress challenge were unrelated to cortisol con-
centrations. In the present study also it appears cognitive-emotional and 
sleep-related improvements were unrelated to changes in key bio-
markers such as cortisol and BDNF. 
Our research question concerned the capacity of sleep-improving 
interventions to alter symptoms of sleep -disordered breathings. The 
answer was no. The following are possible reasons for this lack of any 
effect. First, sleep-disordered breathing was assessed by self-reports, 
which by default can be imprecise and biased. Second, even if partici-
pants accurately reported symptoms of OSAs, previous work has shown 
that OSAs in HIV patients receiving MMT are an issue of the central 
neuronal respiratory controller (Gutierrez et al., 2019; Teichtahl and 
Wang, 2007; Wang and Teichtahl, 2007; Wang et al., 2005). Given this, 
it is highly unlikely that sleep-improving medications or 
psycho-educative strategies could produce changes in the central 
neuronal respiratory controller or that they could counteract the effect 
of methadone on these neuronal regions and processes. 
Improvements in sleep-related dimensions were found most clearly 
in the SHT and SHT + TRAZ conditions, and this deserves particular 
attention. First, it is possible that psycho-educative group interventions 
in themselves support and enhance cognitive-emotional and behavioral 
functioning. For example, Pashaei et al. (2013) showed that, among 
opioid dependent patients undergoing MMT, relapse rates for drug use 
were significantly lower among those regularly involved in 
cognitive-behavioral group interventions than among those in the con-
trol condition. Second, Zhang et al. (2019) noted that, among 
opioid-dependent and HIV patients, daytime structures and social 
adherence to group activities and interventions produced improvements 
in life style. It is possible that in the present study such 
cognitive-emotional, behavioral, social and structural interventions 
likewise helped to improve participants’ daytime structures and activ-
ities. Third, as mentioned above, sleep improvements could be an 
epiphenomenon or a co-occurring effect or both of reductions in 
depression and anxiety. 
The novelty of the findings should be balanced against the following 
limitations. First, sleep disordered breathing such as obstructive sleep 
apnea syndrome (OSAS) was only subjectively assessed with the Berlin 
Questionnaire (Netzer et al., 1999), though this questionnaire is not a 
diagnostic tool; it merely estimates an individual’s risk of suffering from 
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OSAS and provides only an approximate estimation of risk. However, 
Hassamal et al. (2016) observed that OSAS is a common issue for in-
dividuals undergoing MMT, and it not only has adverse effects on sleep 
quality but also on a wide range of physiological and psychological 
functions. Indeed, OSAS is of critical concern because both in children 
and adults it is associated with an increased risk of systemic comor-
bidities such as cardiovascular diseases, hypertension, metabolic syn-
drome, and cognitive impairments (Dewan et al., 2015; Pedrosa et al., 
2014). The most important epidemiological risk factors for OSAS are 
obesity and male gender (Davies, 1990; Reichmuth et al., 2005). 
Furthermore, OSAS plays an important role in the emergence and 
maintenance of hypertension, while snoring is a risk factor for hyper-
tension independent of body mass index, apnea/hypopnea index (AHI), 
or age (Khazaie et al., 2018). Given this, future studies should assess 
OSAS in an accurate and objective fashion. 
Second, studies in psychotherapy show that behavioral change is 
difficult to achieve and requires modifications at the cognitive- 
emotional level (Grawe, 2004, 2007; Grawe et al., 1994). Given this, 
it remains unclear to what extent the interventions produced 
cognitive-emotional changes related to sleep habits, including the 
motivation and capacity to translate the substance of instructions during 
SHT into behavior. 
Third, in order to improve sleep patterns and well-being, Merrill 
et al. (2007) employed an intensive, four week program involving 10 h 
of moderate to vigorous physical activity and regular 
cognitive-behavioral psycho-educative training in stress-management 
and emotion regulation. Compared to the baseline condition, partici-
pants (N = 2624; age range: 30–80 years) displayed improvements in 
sleep duration, sleep quality, and coping with stress and emotion. Given 
their findings it is possible that for individuals with HIV undergoing 
MMT and with fluctuating wake-sleep-patterns this very intensive form 
of intervention might have produced greater changes in their sleep and 
psychological functioning. 
Fourth, the study design was such that participants were always 
aware of which study condition they had been assigned to; thus, it is 
conceivable that outcome expectations and motivational cognitive- 
emotional processes might have biased the outcome. 
Fifth, and relatedly, it is also possible that latent and unassessed 
physiological, psychological and behavioral dimensions might have 
biased two or more dimensions in the same or opposite direction. 
Sixth, future studies should make a more thorough assessment of 
participants’ sleep habits, and cognitive-emotional characteristics 
related to sleep, in particular those related to pre-sleep (Harvey, 2000; 
Harvey and Payne, 2002; Harvey and Tang, 2012) and 
sleep-procrastination (Herzog-Krzywoszanska and Krzywoszanski, 
2019; Li et al., 2020; Nauts et al., 2019; van Eerde and Venus, 2018). 
Seventh, for cultural (wards are gender-separated) and methodo-
logical reasons (investigating a homogeneous sample), we assessed only 
males. Our findings are therefore not generalizable to females with HIV 
and undergoing MMT, and future studies should also assess females. 
Eighth, while we were unable to find improvements on all di-
mensions, notably OSAS, daytime sleepiness, insomnia, working mem-
ory performance and biomarkers such as cortisol, BDNF and CD4+, we 
also found no further deterioration. A control condition with no in-
terventions or social support would therefore have been helpful to settle 
whether the zero-improvements on these dimensions were in fact pre-
ventions of additional deterioration. 
Last, to explore and detect associations between sleep patterns, 
depression, anxiety, cognitive performances, and biomarkers between 
and within the three study groups and over time, a series of correlational 
computations would have been a reasonable option. However, such 
analyses were considered to be too fine-grained. Accordingly, such re-
sults were not reported. 
5. Conclusions 
In a clinical sample of males with HIV and opioid use disorder (OUD) 
and undergoing methadone maintenance therapy (MMT) (MMMMT 
(MMT), specific sleep-improving interventions improved sleep, reduced 
symptoms of depression and anxiety and enhanced cognitive perfor-
mance. Beneficial changes were most apparent when sleep hygiene 
training was included. 
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